TMCI Stock Forecast & Price Target

Treace Medical Concepts Inc. has experienced a 7.0% year-over-year increase in active surgeon users, reaching approximately 3,285, despite a 9% decline in utilization per surgeon, suggesting potential for enhanced revenue generation as market conditions improve. The company is positioned to capitalize on opportunities for margin expansion by increasing average selling prices (ASPs) of its products and capturing a larger market share in complementary foot and ankle procedures. With a strengthened sales force and strategic initiatives aimed at boosting direct-to-consumer programs and physician education, Treace anticipates positive growth prospects in revenue driven by both existing and new offerings, including its minimally invasive (MIS) Osteotomy system.

Treace Medical Concepts is facing a concerning financial outlook, with a projected revenue decline of approximately 10% year-over-year for the fourth quarter, despite this period being historically strong for the company. Additionally, customer surveys indicate an average decline of around 7% in bunion procedure volumes, likely due to deferment of elective surgeries, which has prompted a reduction in revenue guidance for FY25 from $224-230 million to $211-213 million. This downward revision follows a series of guidance resets, suggesting a challenging growth environment ahead, with expectations of negative year-over-year growth in 2026, further contributing to a potentially stagnant market valuation.